Evaluation of in vivo Neuroinflammation Using 18F-NOS (PET/CT) in HIV Positive and Negative Subjects with Opioid Use Disorder and Healthy Controls

Evaluation of in vivo Neuroinflammation Using 18F-NOS (PET/CT) in HIV Positive and Negative Subjects with Opioid Use Disorder and Healthy Controls
Recruiting
18 years - 80 years
All
Phase 1
60 participants needed

Brief description of study

Study Purpose: The goal of this study is to learn more about how opiate use and HIV affects inflammation in the brain. We will study this using a type of Positron Emission Tomography (PET/CT) scan using a radioactive imaging drug called 18F-NOS that can be used to measure inflammation in the brain. Procedures: If you agree to join the study, you will be asked to complete the following research procedures: • 18F-NOS PET/CT of the brain • Placement of an arterial catheter to perform blood draws during the scan • Blood draw for measurement of research inflammatory markers or other testing • Brain MRI scan if you have not had one within 1 year that is up to study standards

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: HIV,opioid use,healthy controls
  • Age: 18 years - 80 years
  • Gender: All


Updated on 19 Feb 2024. Study ID: 842717

Find a site

Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Message For Non Enrolling By Invitation Trial

Select a study center that’s convenient for you, and get in touch with the study team.